LB Pharmaceuticals, Inc. (LBRX)
NASDAQ:LBRX
Want to see LBRX full AI Analyst Report?
Top Page
LB Pharmaceuticals, Inc.
(NASDAQ:LBRX)
Select Model
Select Model
Rating:49Neutral
Price Target:
$29.00
▼(-4.98% Downside)
Action:Reiterated
Date:06/10/26
The score is held back primarily by weak financial performance (no revenue, ongoing losses and cash burn) despite a much improved 2025 balance sheet. Technical signals are neutral-to-modestly supportive, while valuation remains challenged due to negative earnings; corporate events add a small governance/leadership positive.
Positive Factors
Strengthened 2025 balance sheet
A materially positive equity base and very low debt in 2025 provide durable financial flexibility for a clinical-stage biotech. This reduces near-term solvency risk, supports continued R&D spend and partnership negotiations, and lengthens runway versus pre-2025 capital constraints.
Negative Factors
No revenue generation
Persistent absence of product revenue means the company remains dependent on financing to fund operations indefinitely until commercialization. This structural shortfall limits self-sustaining cash flows, raises execution risk for trials and commercialization, and increases future dilution probability.
Read all positive and negative factors
Positive Factors
Negative Factors
Strengthened 2025 balance sheet
A materially positive equity base and very low debt in 2025 provide durable financial flexibility for a clinical-stage biotech. This reduces near-term solvency risk, supports continued R&D spend and partnership negotiations, and lengthens runway versus pre-2025 capital constraints.
Read all positive factors
LB Pharmaceuticals, Inc. (LBRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$814.99M
Dividend YieldN/A
Average Volume (3M)239.05K
Price to Earnings (P/E)―
Beta (1Y)1.39
Revenue GrowthN/A
EPS Growth35.45%
CountryUS
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding28,676,653
10 Day Avg. Volume318,803
30 Day Avg. Volume239,047
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)1.87
Price to Sales (P/S)0.00
P/FCF Ratio-15.97
Enterprise Value/Market Cap0.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.91K
Enterprise Value/Ebitda-12.42
Forecast
1Y Price Target
$46.83Price Target Upside53.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
LB Pharmaceuticals, Inc. Business Overview & Revenue Model
Company Description
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, th...
How the Company Makes Money
null...
LB Pharmaceuticals, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -82.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -39.05M | -24.88M | -63.01M | -1.45M | -12.19M |
| Net Income | -39.17M | -25.20M | -63.10M | -6.28M | -14.35M |
Balance Sheet | |||||
| Total Assets | 393.48M | 312.93M | 33.53M | 45.66M | 21.49M |
| Cash, Cash Equivalents and Short-Term Investments | 365.64M | 295.21M | 28.00M | 43.29M | 21.40M |
| Total Debt | 3.47M | 3.57M | 3.70M | 0.00 | 24.15M |
| Total Liabilities | 14.79M | 11.62M | 128.09M | 80.13M | 50.30M |
| Stockholders Equity | 378.69M | 301.31M | -94.55M | -34.47M | -28.81M |
Cash Flow | |||||
| Free Cash Flow | -51.71M | -35.26M | -53.82M | -12.12M | -2.73M |
| Operating Cash Flow | -51.63M | -35.21M | -53.05M | -12.09M | -2.73M |
| Investing Cash Flow | -42.41M | -39.89M | 23.23M | -28.01M | 123.00K |
| Financing Cash Flow | 396.39M | 302.56M | 38.31M | 33.68M | 22.96M |
LB Pharmaceuticals, Inc. Risk Analysis
LB Pharmaceuticals, Inc. disclosed 85 risk factors in its most recent earnings report. LB Pharmaceuticals, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
condition or results of operations, which may adversely affect investor confidence in us and, as a result, the value of our common stock. Q1, 2026
LB Pharmaceuticals, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
LBRX
LB Pharmaceuticals, Inc.
28.50
11.70
69.64%
HIND
Vyome Holdings
2.17
-9.31
-81.10%
ENVB
Enveric Biosciences
1.48
-13.76
-90.29%
PBM
Psyence Biomedical
3.30
-23.98
-87.90%
SPRC
SciSparc Ltd.
8.34
-50.74
-85.88%
LB Pharmaceuticals, Inc. Corporate Events
Executive/Board ChangesShareholder Meetings
LB Pharmaceuticals Stockholders Approve Directors and Auditor
Positive
Jun 9, 2026
LB Pharmaceuticals, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 3, 2026, where a quorum was present and shareholders voted on key governance matters. Stockholders elected three Class I directors—Robert A...
Executive/Board Changes
LB Pharmaceuticals Announces Director Zachary Prensky’s Planned Retirement
Neutral
Mar 16, 2026
On March 13, 2026, LB Pharmaceuticals, Inc. announced that director Zachary Prensky plans to retire from the Board and will not stand for reelection at the 2026 annual meeting of stockholders, with his term ending at that meeting. The company emph...
Business Operations and StrategyExecutive/Board Changes
LB Pharmaceuticals adds neuroscience leader to board, governance
Positive
Mar 10, 2026
On March 6, 2026, LB Pharmaceuticals appointed veteran neuroscience drug development executive Robert A. Lenz, M.D., Ph.D., to its Board of Directors as a Class I director and member of the Nominating and Corporate Governance Committee, compensati...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.